Targeting MEST using cobicistat as a therapeutic strategy for gastric cancer through suppressing NF-κB signaling
Frontiers in Oncology · 04.08.2026 · 16
DOI: 10.3389/fonc.2026.1901635 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 04.08.2026. Verfasst von Hongtai Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Gastric cancer (GC) constitutes a substantial global public health challenge, and the lack of tractable molecular targets limits therapeutic progress. Mesoderm-Specific Transcript (MEST) has been implicated in tumor-related signaling, yet its functional role and druggability in GC remain undefined.
Methods
The analyses of GC tissue microarrays and cohorts were performed to evaluate MEST expression and its clinical significance. CRISPR/Cas9-mediated MEST knockout was used to characterize its oncogenic functions in GC cells and xenograft models. Integrated RNA sequencing and pathway analysis was utilized to elucidate signaling pathways under the regulation of MEST. A structure-guided virtual screen combined with SPR binding and phenotypic assays were employed to discover small molecules targeting MEST. The therapeutic effects and mechanism of the lead compound were evaluated using GC cell lines, patient-derived organoids, cell-derived xenograft (CDX), and patient-derived xenograft (PDX) models.
Methods
MEST expression in GC tissues was elevated and linked to poor prognosis. Functionally, genetic ablation of MEST impaired GC cell proliferation, invasion, migration, and suppressed tumor growth in CDX models. Screening of approved-compound libraries identified cobicistat as a previously unrecognized high-affinity candidate MEST-inhibitory compound. Cobicistat suppressed tumor growth across a panel of preclinical GC models, including cell lines, organoids, CDX and PDX. Mechanistically, MEST may drive GC progression by activating the NF-κB pathway, whereas cobicistat may antagonize MEST binding and blocked NF-κB pathway.
Conclusion
MEST functions as a key oncoprotein driving GC progression via NF-κB activation. Cobicistat, a candidate MEST-inhibitory compound, exhibits favorable preclinical efficacy and safety, providing a promising candidate for targeted GC therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of General Surgery, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
- Cuiying Biomedical Research Center, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
- Gansu Province High-Altitude High-Incidence Cancer Biobank, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
- Department of General Surgery, Hexi University & Zhangye People's Hospital, Zhangye, China.
Zitieren
APA
Cao, H., Ye, H., Zhang, W., Cai, W., Han, H., Zhu, J., Dong, Y., Shi, W., Zhang, Z., Qin, L., & Jiao, Z. (2026). Targeting MEST using cobicistat as a therapeutic strategy for gastric cancer through suppressing NF-κB signaling. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1901635
Vancouver
Cao H, Ye H, Zhang W, Cai W, Han H, Zhu J, et al. Targeting MEST using cobicistat as a therapeutic strategy for gastric cancer through suppressing NF-κB signaling. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1901635
BibTeX
@article{Cao2026,
author = {Cao, Hongtai and Ye, Huili and Zhang, Wentao and Cai, Weiwen and Han, Haobo and Zhu, Junmin and Dong, Yuman and Shi, Wengui and Zhang, Zhenming and Qin, Long and Jiao, Zuoyi},
title = {Targeting MEST using cobicistat as a therapeutic strategy for gastric cancer through suppressing NF-κB signaling},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1901635}
}
EUVIMED